Recent discussions on X about Pulse Biosciences (PLSE) have centered around the company's latest milestone with the FDA granting Investigational Device Exemption (IDE) approval for its nsPFA Cardiac Surgery System study targeting atrial fibrillation. Many users have expressed optimism about the potential impact of this development on the company's future, highlighting the innovative nature of the technology. The buzz on the platform reflects a keen interest in how this could position Pulse Biosciences in the medical device sector.
Additionally, there has been notable chatter about insider activity, with a director's recent purchase of shares worth millions catching attention. Some on X speculate that this move signals strong confidence in the company's direction, while others remain cautious, awaiting further clinical data. The conversation continues to evolve as investors weigh the risks and rewards of this emerging player in bioelectric medicine.
Note: This discussion summary was generated from an AI condensation of post data.
Pulse Biosciences Insider Trading Activity
Pulse Biosciences insiders have traded $PLSE stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $PLSE stock by insiders over the last 6 months:
- ROBERT W DUGGAN purchased 34,659 shares for an estimated $508,100
- DARRIN UECKER (Chief Technology Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $485,700.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Pulse Biosciences Hedge Fund Activity
We have seen 40 institutional investors add shares of Pulse Biosciences stock to their portfolio, and 41 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 380,693 shares (+45.2%) to their portfolio in Q2 2025, for an estimated $5,744,657
- INVESCO LTD. removed 214,490 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,451,144
- MILLENNIUM MANAGEMENT LLC removed 86,574 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,306,401
- RENAISSANCE TECHNOLOGIES LLC removed 67,800 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,023,102
- SQUAREPOINT OPS LLC removed 51,418 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $775,897
- MORGAN STANLEY added 45,291 shares (+89.8%) to their portfolio in Q2 2025, for an estimated $683,441
- GEODE CAPITAL MANAGEMENT, LLC added 33,744 shares (+7.2%) to their portfolio in Q2 2025, for an estimated $509,196
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
